Pregnancy

Podcast Episode 27: How Dexcom Real-Time CGM Supports Pregnant Patients and Enhances Diabetes Management

alexa.stelzer — Wed, 18 Jun 2025 19:00:25 +0000

Podcast Episode 27: How Dexcom Real-Time CGM Supports Pregnant Patients and Enhances Diabetes Management

07/03/2025

alexa.stelzer Wed, 06/18/2025 - 19:00

Expert Insights from Rachel Stahl Salzman

Guest Speakers: Rachel Stahl Salzman, Registered Dietitian and Certified Diabetes Care and Education Specialist at Weill Cornell

Real-Time Real Talk is intended for healthcare professionals in the US.

In this episode of Real-Time Real Talk, host Cher Pastore is joined by Rachel Stahl Salzman, a registered dietitian and certified diabetes care and education specialist at Weill Cornell, to explore how real-time CGM is transforming care for pregnant patients and beyond. The discussion includes:

How CGM supports people with type 1, type 2, prediabetes, and gestational diabetes.
Insights from Rachel’s study presented at ATTD on CGM use in pregnancy.
How biosensor technology personalizes care and empowers patients and providers.
The role of CGM in driving behavior change through real-time feedback.

Listen to the full episode here – available on Apple Podcasts and Spotify. Subscribe to never miss an episode!

^MAT-9580

Podcast

Clinical Evidence

Diabetes Technology

Pregnancy

Podcasts

Yes

Related Resources

Podcast Episode 20: Navigating Pregnancy with Diabetes - CGM Strategies for Success

Podcast Episode 26: Type 2 Diabetes Management with CGM (ATTD)

Premium Content

Off

The Role of CGM and Automated Insulin Delivery (AID) Systems in Pregnancy

OlgaDalisay — Tue, 21 May 2024 17:32:55 +0000

The Role of CGM and Automated Insulin Delivery (AID) Systems in Pregnancy

05/24/2024

OlgaDalisay Tue, 05/21/2024 - 17:32

A perspective from the United Kingdom

^{The information you see or hear at this event provides details about medical products which are not available in all countries, may have different indications, and/or have not received approval or market clearance by all governmental regulatory bodies throughout the world. Nothing shown or stated herein should be construed as a solicitation, advertisement, or promotion of any product, or of an indication of any specific use for any product, which is not authorized by the laws and regulations of the country where you reside.}

^{The content may include the presenter’s own experience sharing and data – please do not record or distribute the presentation slides.}

This short presentation was delivered during the recent ATTD Diabetes Congress in Italy.

Managing diabetes during pregnancy is critical for maternal and fetal health. Pregnancy induces physiological changes that affect insulin sensitivity, complicating glycemic control.¹ Poorly managed diabetes can lead to adverse outcomes such as preeclampsia, preterm birth, and congenital malformations.² Utilizing continuous glucose monitoring (CGM) technology allows for real-time glucose tracking, facilitating tighter glycemic control.³ This proactive management is essential in minimizing hyperglycemia and hypoglycemia, thus improving both maternal and neonatal outcomes.⁴ Close monitoring and interdisciplinary care are vital for optimizing pregnancy outcomes in women with diabetes.⁵

Dr Helen Murphy is a Professor of Medicine (Diabetes and Antenatal Care) at the University of East Anglia, and a practicing clinician (Norfolk & Norwich University Hospital NHS Trust), Norwich, UK.

She runs a diabetes pregnancy research program which aims to support women with diabetes to achieve the pregnancy glucose targets required for optimal mother and baby health outcomes. She co-led the CONCEPTT Continuous Glucose Monitoring (CGM) trial. CONCEPTT demonstrated health benefits for mothers with type 1 diabetes (T1D), their newborn infants and the potential for substantial healthcare cost savings. In addition to scientific contributions, building research infrastructure and supporting the next generation of clinical academics, data from CONCEPTT led to international changes in clinical practice, CGM is now the recognized standard of care for pregnant women with T1D.

In this short ~20 min presentation, Dr Murphy will talk about the specifics of diabetes management in pregnant individuals across the United Kingdom, including:

National Diabetes in Pregnancy Audit
CGM use before and during Type 1 diabetes pregnancy
AiDAPT randomized trial results

^{Catalano, P. M., & Tyzbir, E. D. (1991). Effects of pregnancy on insulin sensitivity and beta-cell function in women with and without gestational diabetes.}^{American Journal of Obstetrics and Gynecology}^{, 165(3), 579-585.}
^{Reece, E. A., Leguizamon, G., & Wiznitzer, A. (2009). Gestational diabetes: the need for a common ground.}^{The Lancet}^{, 373(9677), 1789-1797.}
^{Voormolen, D. N., de Wit, L., van Rijn, B. B., Koster, M. P., de Valk, H. W., & Franx, A. (2018). Continuous glucose monitoring during pregnancy: An overview of recent studies.}^{Journal of Diabetes Science and Technology}^{, 12(5), 955-960.}
^{Murphy, H. R., et al. (2008). Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial.}^BMJ^{, 337, a1680.}
^{Yogev, Y., & Langer, O. (2008). Pregnancy outcome in diabetic patients.}^{Best Practice & Research Clinical Obstetrics & Gynaecology}^{, 22(6), 1041-1057}

Expert Presentations

Expert Presentations - Automated Insulin Delivery

Expert Presentations - Data Interpretation

Clinical Evidence

Clinical Evidence - Automated Insulin Delivery

Pregnancy

Premium Content

Performance of the Dexcom G7 CGM System in Pregnant Women with Diabetes

alexa.stelzer — Thu, 21 Mar 2024 18:45:54 +0000

Performance of the Dexcom G7 CGM System in Pregnant Women with Diabetes

03/25/2024

alexa.stelzer Thu, 03/21/2024 - 18:45

Pregnancies complicated by suboptimal glucose control are associated with higher rates of maternal and neonatal complications. Dexcom G7 can support glycemic management and is safe and accurate during pregnancy.

In this Research Spotlight, we are highlighting a recent study:

Polsky S, et al. Diabetes Technol Ther. Published online Feb 5, 2024 ahead of print. doi:10.1089/dia.2023.0516

This study aims to evaluate the safety and efficacy of Dexcom G7 CGM system in pregnant women with type 1 diabetes, type 2, and gestational diabetes mellitus (GDM).

Methods:

Data was obtained from 96 Dexcom G7 sensors worn by pregnant women with type 1, type 2, or gestational diabetes. CGM values were compared with glucose values from the YSI comparator instrument at three separate times during the sensors' 10-day wear.

Outcomes Measured:

The primary and secondary endpoints of the study was proportion of CGM values in the 70-180 mg/dL range within:

% 15 / 15 YSI
% 20 / 20 YSI

Results:

Dexcom G7 demonstrated accuracy during pregnancies with diabetes when compared to YSI results with no statistically significant difference between gestational age, A1C levels, different BMI values, or type of diabetes.*

Key Takeaways:

The G7 system is accurate and safe during pregnancies complicated by diabetes and does not require confirmatory fingerstick^§ testing.
Dexcom CGM is an accurate and safe tool for patients on medication, with fear of hypoglycemia during pregnancy.
CGM accuracy lasted full 10 day wear.

Download Resource

^{§ Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings}

^{*Analysis restricted to 2,102 matched pairs with CGM values in the 40-400 mg/dL range using relative differences for YSI values ≥100 mg/dL and absolute differences for YSI values <100 mg/dL. A1C, glycated hemoglobin or HbA1C; BMI, body mass index; CGM, continuous glucose monitoring; GDM, gestational diabetes mellitus; T1D, type 1 diabetes; T2D, type 2 diabetes; YSI, Yellow Springs Instrument.}

Research Spotlight

Clinical Evidence

Pregnancy

Training Resources

dexcom-g7-pregnancy-accuracy-study-infographic-mat-2644.pdf

Yes

Premium Content

Podcast Episode 20: Navigating Pregnancy with Diabetes - CGM Strategies for Success

OlgaDalisay — Wed, 20 Mar 2024 19:52:19 +0000

Podcast Episode 20: Navigating Pregnancy with Diabetes - CGM Strategies for Success

03/20/2024

OlgaDalisay Wed, 03/20/2024 - 19:52

Guest Speaker: Dr. Kristin Castorino

Real-time real talk is intended for healthcare professionals in the US.

Tune in to the latest episode of Real Time Real Talk with your host Cher Pastore, MS, RD, CDCES, BC-ADM. In this episode she takes a deep and insightful look at the ever-evolving landscape of Continuous Glucose Monitoring (CGM) systems specifically within pregnancy with our guest, Dr. Kristin Castorino.

They explore in detail how this technology benefits pregnant patients with diabetes, focusing on the practicality of using devices like Dexcom G7 and how they aid both clinicians and patients in navigating this complex yet essential side of prenatal care. Get a first-hand perspective on the benefits, challenges and the road ahead in diabetes care as Cher and Kristin delve into how CGM systems make data interpretation easier.

They also discuss the data abundance and the changes needed to mitigate the information overload it can often cause. Finally, Kristin discusses common misconceptions about CGM, the key role played by insurance coverage in the adoption of CGMs, and takes a look into the promising developments in the near future. From debunking myths and clarifying concerns about CGM to emphasizing how this technology feeds into a more integrated care environment, this is an episode you won't want to miss.

Read more about Dr. Castorino's work in SIGMA's Research Spotlight: Performance of the Dexcom G7 CGM System in Pregnant Women with Diabetes.

Podcast

Clinical Evidence

Pregnancy

Podcasts

Yes

Kristin Castorino, DO

Dr. Castorino is a Senior Research Physician at Sansum Diabetes Research Institute. Dr. Castorino received her medical degree from Touro University College of Osteopathic Medicine in Vallejo, California, followed by a traditional rotating internship with the University of Nevada Reno’s Family Medicine Program and Internal Medicine residency at Santa Barbara Cottage Hospital. With mentorship from Dr. Lois Jovanovič, Dr. Castorino’s primary research interests include diabetes and pregnancy, diabetes technology and artificial pancreas research. Dr. Castorino was an investigator for the CONCEPTt study and is currently an investigator for the LOIS-P Study (NCT03761615) as well as Automated Insulin Delivery in Pregnant Patients with Type 1 Diabetes with Extension Into Outpatient at Home (NCT04492566). Dr. Castorino has served as an investigator for a multitude of CGM accuracy studies over her 13 years at SDRI and has been delighted to move into evaluation of continuously monitoring alternate analytes such as continuous ketone monitoring.

Related Resources

Performance of the Dexcom G7 CGM System in Pregnant Women with Diabetes

The Role of CGM and Automated Insulin Delivery (AID) Systems in Pregnancy

Premium Content

Off

EASD 2023: Pregnancy Outcomes and Accuracy - The AiDAPT Study

OlgaDalisay — Mon, 23 Oct 2023 16:50:27 +0000

EASD 2023: Pregnancy Outcomes and Accuracy - The AiDAPT Study

10/23/2023

OlgaDalisay Mon, 10/23/2023 - 16:50

_{The information you see or hear at this event provides details about medical products which are not available in all countries, may have different indications, and/or have not received approval or market clearance by all governmental regulatory bodies throughout the world. Nothing shown or stated herein should be construed as a solicitation, advertisement, or promotion of any product, or of an indication of any specific use for any product, which is not authorized by the laws and regulations of the country where you reside.}

_{The content may include the presenter’s own experience sharing and data – please do not record or distribute the presentation slides.}

To date, there is limited clinical evidence about the benefits of CGM in pregnant patients. In this 25 min presentation, Carol Levy, MD, CDCES, will discuss currently available data on pregnant women with Type 1 diabetes, and share new data that came out of using the latest generation of real-time CGM.

Presentation outline:

Introduction of CGM use in pregnancy
Research supporting the use of Dexcom G7 in pregnant women with diabetes
Clinical insights using CGM in pregnancies with diabetes
Review of AiDAPT study

Clinical Evidence

Clinical Evidence - Type 1 Diabetes

Expert Presentations

Expert Presentations - Type 1 Diabetes

Pregnancy

EASD 2023

Carol Levy, MD, CDCES

Dr. Levy is the Director of the Mount Sinai Diabetes Center and Type 1 Diabetes Clinical Research. She is an expert in type 1 diabetes and diabetes in pregnancy as well as general endocrinology. She has over 20 years experience managing patients with these conditions.

Premium Content